4559 ZERIA PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4559

TSE Prime

ZERIA PHARMACEUTICAL CO.,LTD.

2,147

JPY

+10

(+0.47%)

Apr 8, 9:33 am JST

14.55

USD

Apr 7, 8:33 pm EDT

Result

PTS

outside of trading hours

2,150.1

Apr 8, 9:32 am JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	52,757	3,475	3,208	3,143	68.2	34	May 11, 2021	J-GAAP
Mar, 2022	59,532	6,366	5,935	3,961	87.8	35	May 11, 2022	J-GAAP
Mar, 2023	68,383	9,014	7,579	6,195	140.3	40	May 11, 2023	J-GAAP
Mar, 2024	75,725	9,621	8,513	7,731	175.4	44	May 9, 2024	J-GAAP
Mar, 2025 Guidance	86,500	12,000	12,000	9,000	204.2	46	Feb 5, 2025	J-GAAP
YoY	+14.2%	+24.7%	+41.0%	+16.4%	+16.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 10, 2019	65,000	5,000	5,000	3,800	34	J-GAAP
Results	May 21, 2020	60,426	4,094	3,879	2,925	34	J-GAAP
Mar, 2021	May 21, 2020	Available in future release
	Aug 4, 2020
	Feb 5, 2021
Results	May 11, 2021
Mar, 2022	May 11, 2021
	Nov 1, 2021
Results	May 11, 2022
Mar, 2023	May 11, 2022
	Feb 2, 2023
Results	May 11, 2023
Mar, 2024	May 11, 2023
Results	May 9, 2024
Mar, 2025	May 9, 2024	83,000	10,000	10,000	7,800	46	J-GAAP
	Nov 5, 2024	86,000	11,000	11,000	8,500	46	J-GAAP
	Feb 5, 2025	86,500	12,000	12,000	9,000	46	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	56,183	+2.4	Available in future release
Mar, 2001	55,766	-0.7
Mar, 2002	53,837	-3.5
Mar, 2003	55,055	+2.3
Mar, 2004	54,375	-1.2
Mar, 2005	56,209	+3.4
Mar, 2006	55,545	-1.2
Mar, 2007	52,757	-5.0
Mar, 2008	49,721	-5.8
Mar, 2009	47,670	-4.1
Mar, 2010	50,745	+6.5
Mar, 2011	49,482	-2.5
Mar, 2012	53,169	+7.5
Mar, 2013	53,317	+0.3
Mar, 2014	61,996	+16.3
Mar, 2015	61,012	-1.6
Mar, 2016	62,475	+2.4
Mar, 2017	64,849	+3.8
Mar, 2018	64,568	-0.4
Mar, 2019	61,831	-4.2
Mar, 2020	60,426	-2.3
Mar, 2021	52,757	-12.7
Mar, 2022	59,532	+12.8
Mar, 2023	68,383	+14.9
Mar, 2024	75,725	+10.7
Mar, 2025 Guidance	86,500	+14.2	12,000	+24.7	12,000	+41.0	204.2	+16.4

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	68,383	9,014	13.2	10.30	4.78	0.53	140.3
Mar, 2024	75,725	9,621	12.7	10.66	5.41	0.53	175.4
Mar, 2025 Guidance	86,500	12,000	13.9	10.58	5.75	0.55	204.2

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	75,725	9,621	8,513	7,731	175.4
Fiscal Year	Mar, 2024	Mar, 2024	Mar, 2024	Mar, 2024	Mar, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	30,926	3,694	2,819	1,846	40.9	18	May 11, 2022	J-GAAP
Oct - Mar, 2022	34,671	3,120	2,397	2,197	49.7	22	May 11, 2023	J-GAAP
Oct - Mar, 2023	39,047	4,294	3,018	2,335	53.0	22	May 9, 2024	J-GAAP
Oct - Mar, 2024 Guidance	44,078	5,541	4,051	2,939	66.7	23	Feb 5, 2025	J-GAAP
YoY	+12.9%	+29.0%	+34.2%	+25.9%	+25.9%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	6,366	6,058	8,950	-2,892	-4,841	11,579	9.32	J-GAAP
Mar, 2023	9,014	10,583	13,157	-2,574	-7,415	16,094	11.92	J-GAAP
Mar, 2024	9,621	8,231	12,183	-3,952	-8,124	18,604	12.36	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	51,729	8,550	6,957	5,980	135.3	91.8	Feb 2, 2023	J-GAAP
Apr - Dec, 2023	57,919	9,490	9,444	8,423	191.1	110.9	Feb 1, 2024	J-GAAP
Apr - Dec, 2024	64,773	10,246	10,661	8,226	186.6	88.8	Feb 5, 2025	J-GAAP
YoY	+11.8%	+8.0%	+12.9%	-2.3%	-2.3%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2023	16,654	464	622	215	4.9	2.8	May 11, 2023	J-GAAP
Apr - Jun, 2023	18,304	2,970	3,355	2,915	66.1	16.2	Aug 3, 2023	J-GAAP
Jul - Sep, 2023	18,374	2,357	2,140	2,481	56.3	12.8	Nov 1, 2023	J-GAAP
Oct - Dec, 2023	21,241	4,163	3,949	3,027	68.7	19.6	Feb 1, 2024	J-GAAP
Jan - Mar, 2024	17,806	131	-931	-692	-15.7	0.7	May 9, 2024	J-GAAP
Apr - Jun, 2024	21,455	3,939	5,459	4,212	95.6	18.4	Aug 1, 2024	J-GAAP
Jul - Sep, 2024	20,967	2,520	2,490	1,849	42.0	12.0	Nov 6, 2024	J-GAAP
Oct - Dec, 2024	22,351	3,787	2,712	2,165	49.1	16.9	Feb 5, 2025	J-GAAP
YoY	+5.2%	-9.0%	-31.3%	-28.5%	-28.5%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2020	14,123	-3.4	Available in future release
Apr - Jun, 2020	12,735	-15.7
Jul - Sep, 2020	12,786	-15.9
Oct - Dec, 2020	14,849	-7.1
Jan - Mar, 2021	12,387	-12.3
Apr - Jun, 2021	13,548	+6.4
Jul - Sep, 2021	15,058	+17.8
Oct - Dec, 2021	16,498	+11.1
Jan - Mar, 2022	14,428	+16.5
Apr - Jun, 2022	16,305	+20.3
Jul - Sep, 2022	17,407	+15.6
Oct - Dec, 2022	18,017	+9.2
Jan - Mar, 2023	16,654	+15.4
Apr - Jun, 2023	18,304	+12.3
Jul - Sep, 2023	18,374	+5.6
Oct - Dec, 2023	21,241	+17.9
Jan - Mar, 2024	17,806	+6.9
Apr - Jun, 2024	21,455	+17.2
Jul - Sep, 2024	20,967	+14.1
Oct - Dec, 2024	22,351	+5.2	3,787	-9.0	2,712	-31.3	49.1	-28.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	22,351	4,163	5,459	4,212	95.6
Fiscal Year	Dec, 2024	Dec, 2023	Jun, 2024	Jun, 2024	Jun, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	1,236.09	44.2	124,282	54,894	48,860	0.95	May 11, 2022	J-GAAP
Mar, 2023	1,484.79	48.5	135,034	65,449	53,462	0.76	May 11, 2023	J-GAAP
Mar, 2024	1,806.33	52.9	150,533	79,622	59,254	0.58	May 9, 2024	J-GAAP
Apr - Dec, 2024	ー	54.3	156,580	85,059	65,497	0.52	Feb 5, 2025	J-GAAP

ZERIA PHARMACEUTICAL CO.,LTD.(4559) Financial Results